Last $45.06 USD
Change Today -0.65 / -1.43%
Volume 263.8K
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:31 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1 Burlington Road

Dublin, 4

Ireland

Phone: 353 1 772 8000

Fax:

Alkermes Public Limited Company operates as an integrated, global biopharmaceutical company. The company has a portfolio of approximately 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders, such as addiction, schizophrenia, and depression. Strategy The company’s business strategy includes forming collaborations to develop and commercialize its products and, in so doing, to access technological, financial, marketing, manufacturing and other resources. Products Marketed Products RISPERDAL CONSTA (risperidone long-acting injection) and INVEGA SUSTENNA/XEPLION (paliperidone palmitate extended-release injectable suspension) are long-acting atypical antipsychotics that incorporate the company’s proprietary technologies. RISPERDAL CONSTA uses the company’s polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. RISPERDAL CONSTA is exclusively manufactured by it and is marketed and sold by Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (Janssen) worldwide. RISPERDAL CONSTA is also approved for the maintenance treatment of bipolar I disorder in approximately 25 other countries worldwide. INVEGA SUSTENNA uses the company’s nanoparticle injectable extended-release technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for once-monthly intramuscular administration. Paliperidone palmitate extended-release for injectable suspension is also approved in the European Union (EU) and other countries worldwide, and is marketed and sold in the EU under the trade name XEPLION. INVEGA SUSTENNA/XEPLION is manufactured and commercialized worldwide by Janssen. AMPYRA/FAMPYRA Dalfampridine extended-release tablets are marketed and sold in the U.S. under the trade name AMPYRA by Acorda Therapeutics, Inc. (Acorda). Prolonged-release fampridine tablets received conditional approval in the EU in 2011 and are marketed and sold outside the U.S. under the trade name FAMPYRA by Biogen Idec. BYDUREON BYDUREON is approved by the U.S. Food and Drug Administration (FDA) and has marketing authorization in the EU for the treatment of type 2 diabetes. BYDUREON, a once-weekly formulation of exenatide, the active ingredient in BYETTA (exenatide), uses the company’s polymer-based microsphere injectable extended-release technology. In February 2014, AstraZeneca plc (AstraZeneca) assumed sole responsibility for the development and commercialization of BYDUREON. VIVITROL VIVITROL is a once-monthly injectable medication approved by the FDA for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The medication uses the company’s polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every four weeks. The company markets and sells VIVITROL in the U.S., and Cilag GmbH International sells VIVITROL in Russia and the Commonwealth of Independent States. The Russian regulatory authorities approved VIVITROL for the treatment of alcohol dependence and for the treatment of opioid dependence. Other Marketed Products Aripiprazole Lauroxil The company is studying aripiprazole lauroxil for the treatment of schizophrenia. Aripiprazole lauroxil is designed to provide once-monthly dosing of a medication that converts in vivo into aripiprazole, a molecule that is commercially available under the name ABILIFY. In January 2014, the company announced plans to commence clinical testing of aripiprazole lauroxil two-month, a new product candidate for the treatment of schizophrenia, in 2014. ALKS 33 ALKS 33 is an oral opioid modulator characterized by limited hepatic metabolism and durable pharmacologic activity in modulating brain opioid receptors. ALKS 33 has completed a phase 2 study in alcohol dependence and is being evaluated as a component of ALKS 5461 and ALKS

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $45.06 USD -0.65

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $60.47 USD -0.99
Impax Laboratories Inc $27.92 USD -0.245
Jazz Pharmaceuticals Plc $143.17 USD -0.1485
Pacira Pharmaceuticals Inc/DE $85.29 USD -1.44
Salix Pharmaceuticals Ltd $132.84 USD +0.58
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.0x
Price/Book 4.9x
Price/Cash Flow 133.0x
TEV/Sales 10.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.